Can a Custom-Made genetic drug slow ALS?

NCT ID NCT07743268

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests a personalized drug called nL-TARDB-006, designed for people with ALS caused by a specific genetic mutation in the TARDBP gene. The drug is an antisense oligonucleotide, which aims to target the genetic cause of the disease. Six participants will receive the treatment, and researchers will track changes in muscle function, breathing, thinking, and survival over 12 months. The goal is to see if this tailored approach can slow the progression of ALS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A personalized antisense oligonucleotide drug called nL-TARDB-006
What this could lead to
If successful, this approach could slow or halt the progression of ALS in people with TARDBP mutations, offering a targeted treatment for a currently incurable disease.
What could go wrong
This is an early-phase, very small trial (6 participants), so results may not generalize. The drug is experimental and may not effectively alter disease course, and there are potential risks from the treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University, Irving Medical Center

    New York, New York, 10032, United States

  • Washington University

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.